AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
IAG beats on Q3 revenue; AstraZeneca discloses 'positive' Phase 3 clinical trial
FTSE 100 futures up 12.50 points to 8,185.0. IAG's Q3 revenue rose 7.9% to €9.33bn, with 15.4% operating profit jump to €2.01bn. AstraZeneca's Texspire phase III trial showed significant nasal polyp reduction. Oaktree Capital urges Indivior board refresh for shareholder value. Health groups call for salt and sugar taxes. AI could displace 1-3m UK private sector jobs. Bentley delays full electrification to 2035. US markets mixed post-Trump victory and Fed rate decision.
tezspire met both co-primary endpoints in phase 3 trial for chronic rhinosinusitis with nasal polyps
Positive Phase 3 WAYPOINT trial results show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients, compared to placebo, with a consistent safety profile.
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo and AstraZeneca awarded 2024 Prix Galien USA for ENHERTU, a HER2-directed ADC, recognized for improving human condition.
Related Clinical Trials:
AstraZeneca Says Phase III WAYPOINT Study Of Tezspire Met Primary Goals
AstraZeneca's Phase III WAYPOINT study of Tezspire in chronic rhinosinusitis with nasal polyps met co-primary endpoints, showing significant reduction in nasal polyps and congestion, with consistent safety profile.
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC
Positive top-line results from the Phase 3 WAYPOINT trial show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients compared to placebo, with a consistent safety profile.
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with ...
Tezspire (tezepelumab) showed significant reduction in nasal polyps and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering a potential new treatment option.
Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen's Tezspire (tezepelumab) met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyp size and congestion. The therapy, a TSLP inhibiting monoclonal antibody, previously received FDA approval for severe asthma and a breakthrough therapy designation for COPD. Tezspire's main competitor is Sanofi and Regeneron's Dupixent, which also treats CRSwCP and other immune-mediated disorders.
© Copyright 2025. All Rights Reserved by MedPath